Physicochemical space for optimum oral bioavailability: Contribution of human intestinal absorption and first-pass elimination

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1098-1108

  Varma, Manthena V S ^a   Obach, R Scott ^a   Rotter, Charles ^a   Miller, Howard R ^a   Chang, George ^a   Steyn, Stefanus J ^a   El Kattan, Ayman ^a   Troutman, Matthew D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA BASE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; FIRST PASS EFFECT; HUMAN; HYDROGEN BOND; INTESTINE ABSORPTION; INTESTINE WALL; IONIZATION; LIPID MEMBRANE; LIPOPHILICITY; MOLECULAR SIZE; MOLECULAR WEIGHT; PERMEABILITY; PHYSICAL CHEMISTRY; SOLUBILITY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS;

EID: 77249122159     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901371v     Document Type: Article

References (53)

1. Beaumont,K.;Smith, D. A.Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr. Opin. Drug Discovery Dev. 2009, 12, 61-71.
2. Mager, D. E. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv. Drug Delivery Rev. 2006, 58, 1326-56.
3. Rostami-Hodjegan, A.; Tucker, G. T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discovery 2007, 6, 140-148.
4. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discovery 2003, 2, 192-204.
5. van De Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44, 1313-1333.
6. Varma, M. V.; Khandavilli, S.; Ashokraj, Y.; Jain, A.; Dhanikula, A.; Sood, A.; Thomas, N. S.; Pillai, O.; Sharma, P.; Gandhi, R.; Agrawal, S.; Nair, V.; Panchagnula, R. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr. Drug Metab. 2004, 5, 375-388.
7. Lombardo, F.; Gifford, E.; Shalaeva, M. Y. In silico ADME prediction: data, models, facts and myths. Mini-Rev. Med. Chem. 2003, 3, 861-875.
8. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
9. Bergstrom, C. A.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 2003, 46, 558-570.
10. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817-834.
11. Linnankoski, J.; Makela, J. M.; Ranta, V. P.; Urtti, A.; Yliperttula, M. Computational prediction of oral drug absorption based on absorption rate constants in humans. J. Med. Chem. 2006, 49, 3674-3681.
12. Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48, 3164-3170.
13. van de Waterbeemd, H. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur. J. Pharm. Sci. 1998, 7, 1-3.
14. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
15. Zhao, Y. H.; Le, J.; Abraham,M. H.; Hersey, A.; Eddershaw, P. J.; Luscombe, C. N.; Butina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J. A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. 2001, 90, 749-784.
16. Galetin, A.; Gertz, M.; Houston, J. B. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin. Drug Metab. Toxicol. 2008, 4, 909-922.
17. Lin, J. H.; Chiba, M.; Baillie, T. A. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 1999, 51, 135-158.
18. Thummel, K. E. Gut instincts: CYP3A4 and intestinal drug metabolism. J. Clin. Invest. 2007, 117, 3173-3176.
19. van Herwaarden, A. E.; van Waterschoot, R. A.; Schinkel, A. H. How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol. Sci. 2009, 30, 223-227.
20. Venkatakrishnan, K.; Von Moltke, L. L.; Greenblatt,D. J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 2001, 41, 1149-1179.
21. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 2008, 36, 1385-1405.
22. Varma, M. V.; Feng, B.; Obach, R. S.; Troutman,M. D.; Chupka, J.; Miller, H. R.; El-Kattan, A. Physicochemical Determinants of Human Renal Clearance. J. Med. Chem. 2009, 52, 4844-4852.
23. Galetin, A.; Hinton, L. K.; Burt, H.; Obach, R. S.; Houston, J. B. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr. Drug Metab. 2007, 8, 685-693.
24. Gertz, M.; Davis, J. D.; Harrison, A.; Houston, J. B.; Galetin, A. Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr. Drug Metab. 2008, 9, 785-795.
25. Ito, K.; Brown, H. S.; Houston, J. B. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol. 2004, 57, 473-486.
26. Varma, M. V.; Sateesh, K.; Panchagnula, R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol. Pharm. 2005, 2, 12-21.
27. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 2007, 8, 676-684.
28. Wenlock,M.C.;Austin,R.P.;Barton,P.;Davis,A.M.;Leeson,P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
29. Leeson, P. D.; Davis, A. M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47, 6338-6348.
30. Doherty, A. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, CA, 2003; Vol. 38, pp 425-441.
31. Camenisch, G.; Alsenz, J.; van de Waterbeemd, H.; Folkers, G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 1998, 6, 317-324.
32. Grime, K.; Riley, R. J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 2006, 7, 251-264.
33. Andrews, C. W.; Bennett, L.; Yu, L. X. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 2000, 17, 639-644.
34. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
35. Refsgaard, H. H.; Jensen, B. F.; Brockhoff, P. B.; Padkjaer, S. B.; Guldbrandt, M.; Christensen, M. S. In silico prediction of membrane permeability from calculated molecular parameters. J. Med. Chem. 2005, 48, 805-811.
36. Stenberg, P.; Norinder, U.; Luthman, K.; Artursson, P. Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 2001, 44, 1927-1937.
37. Abraham, M. H.; Ibrahim, A.; Zissimos, A. M.; Zhao, Y. H.; Comer, J.; Reynolds, D. P. Application of hydrogen bonding calculations in property based drug design. Drug Discovery Today 2002, 7, 1056-1063.
38. Goodwin, J. T.; Conradi, R. A.; Ho, N. F.; Burton, P. S. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. J. Med. Chem. 2001, 44, 3721-3729.
39. Yoshida, F.; Topliss, J. G. QSAR model for drug human oral bioavailability. J. Med. Chem. 2000, 43, 2575-2585.
40. Fisher, M. B.; Labissiere, G. The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr. Drug Metab. 2007, 8, 694-699.
41. Obach, R. S.; Zhang, Q. Y.; Dunbar, D.; Kaminsky, L. S. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab. Dispos. 2001, 29, 347-352.
42. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 2006, 34, 880-886.
43. Shen, D. D.; Kunze, K. L.; Thummel, K. E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Delivery Rev. 1997, 27, 99-127.
44. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
45. Watkins, P. B.; Wrighton, S. A.; Schuetz, E. G.; Molowa, D. T.; Guzelian, P. S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 1987, 80, 1029-1036.
46. van Waterschoot, R. A.; Rooswinkel, R. W.; Sparidans, R. W.; van Herwaarden, A. E.; Beijnen, J. H.; Schinkel, A. H. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab. Dispos. 2009, 37, 2305-2313.
47. van Waterschoot,R. A.; Rooswinkel, R. W.; Wagenaar, E.; van der Kruijssen, C. M.; van Herwaarden, A. E.; Schinkel, A. H. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J. 2009, 23, 224-231.
48. Gomez, D. Y.; Wacher, V. J.; Tomlanovich, S. J.; Hebert, M. F.; Benet, L. Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 1995, 58, 15-19.
49. Hebert, M. F.; Roberts, J. P.; Prueksaritanont, T.; Benet, L. Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 1992, 52, 453-457.
50. von Richter, O.; Burk, O.; Fromm, M. F.; Thon, K. P.; Eichelbaum, M.; Kivisto, K. T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 2004, 75, 172-183.
51. Hall, S. D.; Thummel, K. E.; Watkins, P. B.; Lown, K. S.; Benet, L. Z.; Paine, M. F.; Mayo, R. R.; Turgeon, D. K.; Bailey, D. G.; Fontana, R. J.; Wrighton, S. A. Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos. 1999, 27, 161-166.
52. Knight, B.; Troutman, M.; Thakker, D. R. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge. Curr. Opin. Pharmacol. 2006, 6, 528-532.
53. Wacher, V. J.; Salphati, L.; Benet, L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Delivery Rev. 2001, 46, 89-102.